Cancer Pain - Pipeline Review, H2 2017

Date: October 31, 2017
Pages: 125
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: C2B24D162B9EN
Leaflet:

Download PDF Leaflet

Cancer Pain - Pipeline Review, H2 2017
Cancer Pain - Pipeline Review, H2 2017

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Cancer Pain - Pipeline Review, H2 2017, provides an overview of the Cancer Pain (Central Nervous System) pipeline landscape.

Cancer pain can be defined as a complex sensation that reflects both damage to the body and the body's response to the damage. Pain may arise due to tumor compressing or infiltrating tissue, from treatments and diagnostic procedures, or from skin, nerve and other changes caused by either the body's immune response or hormones released by the tumor. Cancer pain can be treated by analgesic drug therapy, non-opioid analgesics, opioid analgesics, adjuvant drugs, psychotherapy, anesthetic and neurosurgical pain management.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Cancer Pain - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Cancer Pain (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Cancer Pain (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Cancer Pain and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 2, 7, 5, 5, 22, 3 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 4 molecules, respectively.

Cancer Pain (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Cancer Pain (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Cancer Pain (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Cancer Pain (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Cancer Pain (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Cancer Pain (Central Nervous System)
REASONS TO BUY
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Cancer Pain (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Cancer Pain (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


NOTE: Out of security concerns Global Markets Direct requires using corporate email address.
Introduction
Global Markets Direct Report Coverage
Cancer Pain - Overview
Cancer Pain - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Cancer Pain - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Cancer Pain - Companies Involved in Therapeutics Development
Alexza Pharmaceuticals Inc
AngioChem Inc
Aoxing Pharmaceutical Company Inc
Aphios Corp
AstraZeneca Plc
ChironWells GmbH
Colby Pharmaceutical Co
ConSynance Therapeutics Inc
Daewoong Pharmaceutical Co Ltd
Daiichi Sankyo Co Ltd
Dompe Farmaceutici SpA
Fujimoto Pharmaceutical Corp
Grunenthal GmbH
Hisamitsu Pharmaceutical Co Inc
Immupharma Plc
Insys Therapeutics Inc
IntelGenx Corp
iX Biopharma Ltd
Klaria Pharma Holding AB
Komipharm International Co Ltd
KPI Therapeutics Inc
Medlab Clinical Ltd
Nanomerics Ltd
Neurocentrx Pharma Ltd
Nippon Kayaku Co Ltd
Orion Corporation
Pain Therapeutics Inc
Pfizer Inc
Pharmaleads SA
Recordati SpA
Ribomic Inc
Trillium Therapeutics Inc
Virobay Inc
WEX Pharmaceuticals Inc
Cancer Pain - Drug Profiles
(fentanyl + menthol) - Drug Profile
(fentanyl + naloxone) - Drug Profile
ANG-2002 - Drug Profile
AQU-118 - Drug Profile
AZD-8797 - Drug Profile
Cannabis Intractable - Drug Profile
cebranopadol - Drug Profile
CPC-111 - Drug Profile
crotalphine - Drug Profile
CSTI-200 - Drug Profile
dexmedetomidine hydrochloride - Drug Profile
dronabinol - Drug Profile
Drug for Cancer Neuropathic Pain - Drug Profile
DWJ-208 - Drug Profile
fentanyl - Drug Profile
fentanyl citrate - Drug Profile
fentanyl citrate - Drug Profile
fentanyl citrate ER - Drug Profile
gabapentin - Drug Profile
HP-3150 - Drug Profile
HS-198 - Drug Profile
hydromorphone hydrochloride - Drug Profile
HYLP-002 - Drug Profile
INT-0010 - Drug Profile
IPP-102199 - Drug Profile
KL-00406 - Drug Profile
KL-006 - Drug Profile
methadone hydrochloride - Drug Profile
Monoclonal Antibodies to Inhibit TRPV1 for Inflammatory Pain and Cancer Pain - Drug Profile
NM-127 - Drug Profile
PAX-1 - Drug Profile
Peptide to Block Voltage-Dependent N-Type Calcium Channel for Central Nervous System - Drug Profile
Peptide to Target CANP for Cardiovasclar and Cancer Pain - Drug Profile
PL-265 - Drug Profile
PL-37 - Drug Profile
QX-314 - Drug Profile
RBM-004 - Drug Profile
RBM-007 - Drug Profile
resiniferatoxin - Drug Profile
saracatinib difumarate - Drug Profile
Small Molecule 1 to Block Sodium Channels for Cancer Pain and Epilepsy - Drug Profile
Small Molecule 2 to Block Sodium Channels for Cancer Pain and Epilepsy - Drug Profile
Small Molecule 3 to Block Sodium Channels for Cancer Pain and Epilepsy - Drug Profile
tanezumab - Drug Profile
Tetrodotoxin - Drug Profile
tilidine hydrochloride - Drug Profile
TOT-303 - Drug Profile
U-2902 - Drug Profile
VBY-825 - Drug Profile
zucapsaicin - Drug Profile
Cancer Pain - Dormant Projects
Cancer Pain - Discontinued Products
Cancer Pain - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Cancer Pain, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.1), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.2), H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd.1), H2 2017
Products under Development by Companies, H2 2017 (Contd.2), H2 2017
Products under Development by Universities/Institutes, H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Target, H2 2017 (Contd.1), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd.1), H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Cancer Pain - Pipeline by Alexza Pharmaceuticals Inc, H2 2017
Cancer Pain - Pipeline by AngioChem Inc, H2 2017
Cancer Pain - Pipeline by Aoxing Pharmaceutical Company Inc, H2 2017
Cancer Pain - Pipeline by Aphios Corp, H2 2017
Cancer Pain - Pipeline by AstraZeneca Plc, H2 2017
Cancer Pain - Pipeline by ChironWells GmbH, H2 2017
Cancer Pain - Pipeline by Colby Pharmaceutical Co, H2 2017
Cancer Pain - Pipeline by ConSynance Therapeutics Inc, H2 2017
Cancer Pain - Pipeline by Daewoong Pharmaceutical Co Ltd, H2 2017
Cancer Pain - Pipeline by Daiichi Sankyo Co Ltd, H2 2017
Cancer Pain - Pipeline by Dompe Farmaceutici SpA, H2 2017
Cancer Pain - Pipeline by Fujimoto Pharmaceutical Corp, H2 2017
Cancer Pain - Pipeline by Grunenthal GmbH, H2 2017
Cancer Pain - Pipeline by Hisamitsu Pharmaceutical Co Inc, H2 2017
Cancer Pain - Pipeline by Immupharma Plc, H2 2017
Cancer Pain - Pipeline by Insys Therapeutics Inc, H2 2017
Cancer Pain - Pipeline by IntelGenx Corp, H2 2017
Cancer Pain - Pipeline by iX Biopharma Ltd, H2 2017
Cancer Pain - Pipeline by Klaria Pharma Holding AB, H2 2017
Cancer Pain - Pipeline by Komipharm International Co Ltd, H2 2017
Cancer Pain - Pipeline by KPI Therapeutics Inc, H2 2017
Cancer Pain - Pipeline by Medlab Clinical Ltd, H2 2017
Cancer Pain - Pipeline by Nanomerics Ltd, H2 2017
Cancer Pain - Pipeline by Neurocentrx Pharma Ltd, H2 2017
Cancer Pain - Pipeline by Nippon Kayaku Co Ltd, H2 2017
Cancer Pain - Pipeline by Orion Corporation, H2 2017
Cancer Pain - Pipeline by Pain Therapeutics Inc, H2 2017
Cancer Pain - Pipeline by Pfizer Inc, H2 2017
Cancer Pain - Pipeline by Pharmaleads SA, H2 2017
Cancer Pain - Pipeline by Recordati SpA, H2 2017
Cancer Pain - Pipeline by Ribomic Inc, H2 2017
Cancer Pain - Pipeline by Trillium Therapeutics Inc, H2 2017
Cancer Pain - Pipeline by Virobay Inc, H2 2017
Cancer Pain - Pipeline by WEX Pharmaceuticals Inc, H2 2017
Cancer Pain - Dormant Projects, H2 2017
Cancer Pain - Dormant Projects, H2 2017 (Contd.1), H2 2017
Cancer Pain - Dormant Projects, H2 2017 (Contd.2), H2 2017
Cancer Pain - Discontinued Products, H2 2017

LIST OF FIGURES

Number of Products under Development for Cancer Pain, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products by Top 10 Targets, H2 2017
Number of Products by Stage and Top 10 Targets, H2 2017
Number of Products by Top 10 Mechanism of Actions, H2 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Molecule Types, H2 2017
Number of Products by Stage and Molecule Types, H2 2017

COMPANIES MENTIONED

Alexza Pharmaceuticals Inc
AngioChem Inc
Aoxing Pharmaceutical Company Inc
Aphios Corp
AstraZeneca Plc
ChironWells GmbH
Colby Pharmaceutical Co
ConSynance Therapeutics Inc
Daewoong Pharmaceutical Co Ltd
Daiichi Sankyo Co Ltd
Dompe Farmaceutici SpA
Fujimoto Pharmaceutical Corp
Grunenthal GmbH
Hisamitsu Pharmaceutical Co Inc
Immupharma Plc
Insys Therapeutics Inc
IntelGenx Corp
iX Biopharma Ltd
Klaria Pharma Holding AB
Komipharm International Co Ltd
KPI Therapeutics Inc
Medlab Clinical Ltd
Nanomerics Ltd
Neurocentrx Pharma Ltd
Nippon Kayaku Co Ltd
Orion Corporation
Pain Therapeutics Inc
Pfizer Inc
Pharmaleads SA
Recordati SpA
Ribomic Inc
Trillium Therapeutics Inc
Virobay Inc
WEX Pharmaceuticals Inc
Skip to top


Cancer Cachexia - Pipeline Review, H2 2016 US$ 2,000.00 Jul, 2016 · 108 pages

Ask Your Question

Cancer Pain - Pipeline Review, H2 2017
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: